Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

The blockade of immune checkpoints in cancer immunotherapy

2012 • 12,062 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2015 • 7,844 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

2015 • 7,057 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2015 • 5,526 citations

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

2000 • 4,853 citations

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

2014 • 4,720 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

2006 • 3,361 citations

Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

2013 • 3,211 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

2002 • 2,879 citations

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1999 • 2,380 citations

THE B7 FAMILY REVISITED

2005 • 2,239 citations

The PD‐1 pathway in tolerance and autoimmunity

2010 • 2,064 citations

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 • 1,937 citations

Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer

2014 • 1,394 citations

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

2014 • 1,169 citations

The Efficiency of Cox's Likelihood Function for Censored Data

1977 • 1,085 citations

Comparative analysis of two rates

1985 • 1,009 citations

Acquired resistance to TKIs in solid tumours: learning from lung cancer

2014 • 782 citations

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

2015 • 756 citations

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

2015 • 646 citations

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

2014 • 424 citations

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

2012 • 366 citations

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

2015 • 121 citations

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

2014 • 77 citations

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

2015 • 68 citations

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer

2014 • 65 citations

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

2015 • 34 citations